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Abstract 
        Neurodegenerative diseases refer to disorders of the central nervous system (CNS) that are caused 
by neuronal degradations, dysfunctions, or death. Alzheimer’s disease, Parkinson’s disease, and 
Huntington’s disease (APHD) are regarded as the three major neurodegenerative diseases. There is a 
vast body of literature on the causes and treatments of these neurodegenerative diseases. However, the 
main obstacle in developing an effective treatment strategy is the permeability of the treatment 
components to the blood-brain barrier (BBB). Several strategies have been developed to improve this 
obstruction. For example, nanomaterials facilitate drug delivery to the BBB due to their size. They have 
been used widely in nanomedicine and as nanoprobes for diagnosis purposes among others in 
neuroscience. Nanomaterials in different forms, such as nanoparticles, nanoemulsions, solid lipid 
nanoparticles (SLN), and liposomes, have been used to treat the neurodegenerative diseases. This 
review will cover the basic concepts and applications of nanomaterials in the therapy of APHD. 
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1. Introduction  
Neurodegenerative diseases refer to the malfunctions of the CNS commonly caused by neuronal 
dysfunction and death. Major neurodegenerative diseases include APHD (Figure 1). Alzheimer’s disease, 
which is the most prevalent neurodegenerative disease, is the formation of amyloid plaques and 
neurofibrillary tangles by neuro-inflammation. Another indication of the disease is a drop in the levels of 
the neurotransmitter acetylcholine.(1) Mostly, Acetylcholine esterase inhibitors (Rivastigmine, 
Donepezil, and Galantamine) and Memantine are administered as the conventional Alzheimer’s disease 
treatment.(2) The second most common neurodegenerative disease is Parkinson’s disease, which 
typically features a reduced number of dopamine-producing neurons and the presence of Lewy bodies. 
After the appearance of the initial symptoms of Parkinson’s disease, 80% of the dopaminergic neurons 
become destroyed in the substantia nigra. Typical symptoms include rigidity of the body, tremors, slow 
body movements and difficulty in walking. Currently, the disease remains incurable and only few 
symptoms can be treated.(3) Levodopa and dopamine agonists are considered as the main treatment 
for the Parkinson’s disease.(4) Another common neurodegenerative disease is known as Huntington’s 
disease, which is an inherited, autosomal dominant disease that results in jerky movements or chorea, 
dystonia, incoordination, and behavioral changes. Huntington’s disease remains incurable and currently 
only symptomatic treatments exist.(5) Antidopaminergic agents such as Tetrabenazine are the main 
pharmaceutical options for the Huntington’s therapy.(6) 
New therapeutic approaches need to manage these neurodegenerative diseases because the 
current therapies are limited in many areas.(7-10) The BBB , which is the main obstacle met when 
treating diseases of the CNS, is composed of endothelial cells forming tight junctions and separates 
blood from the extracellular fluid of the brain. Furthermore, the permeability of the BBB is selective for 
only certain substances such as nutrients and water. Thus, the barrier prevents the passage of certain 
drugs and therapeutic agents required for the treatment of the disorders related to the CNS.  
Page 3 of 55 Nanoscale
N
an
os
ca
le
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
27
 A
ug
us
t 2
01
8.
 D
ow
nl
oa
de
d 
by
 Io
w
a 
St
at
e 
U
ni
ve
rs
ity
 o
n 
9/
4/
20
18
 6
:2
8:
40
 P
M
.
View Article Online
DOI: 10.1039/C8NR04073G
 4 / 54 
 
The need for new therapeutic approaches of neurodegenerative diseases and the limitations 
caused by the BBB are advancing the use of nanotechnology to establish targeted drug delivery to the 
CNS. Nanotechnology is a field that is developing at a fast pace with respect to its applications in 
medicine.(11-19) Nanomaterials can be highly suitable drug carriers to the brain owing to their physical 
and chemical properties. When manipulated in the right way, nanocarriers can efficiently overcome the 
BBB.(20)  
 
Figure 1 Overall scope of neurodegenerative diseases 
 
Nanoparticles have gained wide interest due to their characteristics including high capacity for drug 
loading, lower or no systematic toxicity, physical and chemical stability, pharmaceutical improvement of 
drug properties, and drug permeabilization.(21-27) However, the penetration of the nanoparticles 
through the BBB highly depends on the type, size, surface chemistry, and polarity of the particles.(28) 
This review discusses the application of drug-loaded nanocarriers in the treatment of neurodegenerative 
diseases.(7) 
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2. Neurodegenerative diseases  
Diseases of the brain can be divided into three main classes, namely the neurodegenerative 
diseases, neuroinflammatory diseases, and neoplastic diseases.(29) Neurodegenerative disorders 
includes different types of conditions which are either sporadic or familial or both and their common 
cause is the continual loss of neuronal subtypes.(30) APHD are known as the most common 
neurodegenerative diseases. For example, Alzheimer’s disease was the cause of dementia in 60% of 
around 24 million people suffering from this disorder in 2005.(31)  
Many studies have reported the impact of neurodegenerative diseases on the BBBs, most plausibly 
through neuro-inflammation.(32) Changes to the BBB not only prevent it from performing its normal 
functions, such as transporting nutrients, its role as a signaling interface, enhancing immune cell entry, 
and maintaining homeostasis, but also hinder the transport of drugs to the CNS to manage 
neurodegeneration. The adopted notion is that the BBB is a static element, i.e., immune to brain 
changes. However, it is likely that the BBB undergoes changes in the case of neurodegeneration, which 
can be interpreted in three different ways: (1) the changes in the BBB may be the consequence of the 
disease; (2) BBB changes account for the disease; or (3) BBB changes participate in the disease 
pathogenesis. Based on evidence from previous findings, the BBB may be involved in the initial 
degenerative process in patients suffering from neurodegenerative diseases. Furthermore, most reports 
have demonstrated that the pathogenic process plays also a role in the dysfunction of the BBB.(33) 
        The exact factors that cause neurodegenerative diseases are still unknown. A family history of 
neurodegenerative diseases increases the risk of developing the disease, which indicates a genetic 
component in the initiation of neurodegeneration. Moreover, the risk of developing a 
neurodegenerative disorder increases with advanced age. Programmed cell death or apoptosis is 
another known cause for neurodegeneration, which is especially observed in Parkinson’s diseases.(29) 
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Neurodegenerative diseases are often associated with neuronal loss and cell death. The neurons that 
survive exhibit changes in nuclear defragmentation, size, shape, chromatin condensation among other 
morphological changes.(29) Neurodegeneration occurs when neurons cannot terminate the apoptotic 
phase due, thus becoming inflamed and necrotic.(34) Different neurodegenerative diseases will be 
discussed in the following paragraphs. 
2.1 Alzheimer’s disease 
Alzheimer’s disease is considered the most common neurodegenerative disease. Currently, there is 
no cure available to treat Alzheimer’s disease, and therapeutic interventions are aimed at managing, i.e., 
mitigating or halting, the associated symptoms. Almost 1% of the population between the ages of 50 to 
70 years suffer from Alzheimer’s disease, and the percentage affected increases to 50% beyond the age 
of 70 years.(20) The primary clinical symptoms detected in patients with Alzheimer’s disease include 
dementia, along with impaired learning and cognition.(29) Later stages of the disease are accompanied 
by increased irritability, confusion and behavioral changes.(30, 35) One particular feature observed in 
the brain of Alzheimer’s disease patient is the presence of a unique pattern of beta-amyloid plaques and 
neurofibrillary tangles. As a result of weakened metabolism of the amyloid precursor protein, beta-
amyloid plaques are formed. It is the aggregation of these plaques that is responsible for the neuronal 
damage. Diffusible ligands and oligomers derived from toxic beta-amyloid plaques contribute directly to 
the neurotoxicity associated with Alzheimer’s disease.(36, 37) The extent of beta-amyloid plaques 
deposition and its location has been directly associated with the amount of neuronal damage and the 
ensuing dementia after diagnosis .(38) Neurofibrillary tangles are paired helical filaments of 
microtubule-associated tau protein that supports neuronal growth under physiological conditions, but 
becomes cytotoxic when hyperphosphorylated.  
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With the progress of Alzheimer’s disease, loss  of cholinergic neurons has been specifically observed, 
indicating that the acetylcholine neurotransmitter is involved in the areas of memory and cognition in 
the brain.(39) Alzheimer’s disease currently has Various treatment options including Donepezil, 
rivastigmine, and galantamine that are frequently prescribed drugs to improve the bioavailability of 
acetylcholine by preventing its breakdown. In addition, currently available drugs included acetylcholine 
esterase inhibitors, which prevent acetylcholine breakdown.(40) Other treatment options that have 
been proposed are the use of anti-inflammatory drugs and antioxidants such as α-tocopherol and non-
steroidal anti-inflammatory medications.(41) Some researchers have shown that immunotherapy can be 
used for the solubilization of beta-amyloid plaques. The future of Alzheimer’s disease treatment lies in 
focusing on preventing beta-amyloid plaque formation or supporting their clearance. Solubilization of 
beta-amyloid plaque has also been successfully induced by humanized monoclonal antibodies such as 
bapineuzumab and solanezumab.(42) 
2.2 Parkinson’s disease 
Another major neurodegenerative brain disorder that affects a large population is Parkinson’s 
disease, which affects 1% of the population of 65 years or older.(20) Pathologically, the loss of 
dopaminergic neurons in the substantia nigra pars compacta causes Parkinson’s disease.(43) The major 
disease symptoms are caused by dopaminergic deficiency in the striatum and include tremors, 
hypokinesia, diminished balance, and rigidity of the body. The main feature of Parkinson’s disease is the 
presence of intracellular eosinophilic inclusions called Lewy bodies, which are abnormal protein 
aggregates. Furthermore, the loss of striatal dopaminergic neurons, which are responsible for motor 
coordination, are the main cause of the disease symptoms.(44) Similarly to Alzheimer’s disease, the 
exact cause of Parkinson’s disease is still unclear. Changes in the CNS associated with Parkinson’s 
disease include protein aggregation, neuroinflammation, oxidative stress, mitochondrial dysfunction, 
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and damages to the BBB integrity. When the parkin and synuclein genes are mutated, the function of 
the ubiquitin-proteasome pathway, which is responsible for the clearance of aggregated and excessive 
proteins, becomes altered. As a result, abnormal proteins aggregate, thus ensuing neuronal death.(45) 
Another theory put forward regarding the mechanism of Parkinson’s disease is related to mitochondrial 
dysfunction. Indeed, aging and toxins accumulation jeopardize the energy resources provided by 
mitochondria. As a result, mitochondrial functioning is adversely affected and the energy required by 
the neurons is not received, thus leading to synuclein production in Parkinson’s disease, which causes 
neuronal damage.(29)  
Currently, only symptomatic therapies are available for patients with Parkinson’s disease, i.e. 
relieving or preventing the associated symptoms, involving the increase of the dopamine action period 
and mirroring dopaminergic actions. Several dopaminergic agonists are available and used for 
Parkinson’s disease treatment.(29) For example, levodopa acts as a dopaminergic agonist and carbidopa 
prevents metabolism at the periphery; when used together, both have the same action as dopamine. 
When administered orally, the pace of levodopa decarboxylation is very high; thus, by the time the drug 
enters the CNS, only a small amount remains unmodified. Therefore, in order to maintain its 
effectiveness, the levodopa dosage should be high enough to enable a substantial unmodified amount 
to reach the CNS. However, increasing the dose is associated with possible side effects, such as 
depression, anxiety, insomnia, agitation, nausea, and vomiting.(3)  
2.3 Huntington’s disease 
Huntington’s disease is a genetic neurodegenerative disease that affects the cognitive and motor 
abilities, with a prevalence of five to seven in every 100,000 people.(5) Similarly to other 
neurodegenerative diseases, Huntington’s disease is associated with a decline in cognitive skills. Other 
common symptoms of the disease are mood swings, psychosis, inability to empathize, inability to 
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maintain relationships, and becoming self-centered. The most characteristic physical symptoms of 
Huntington’s disease are random and uncontrollable movements called chorea. Many of the symptoms 
observed at the onset of Huntington’s disease are similar to those of Schizophrenia, particularly the lack 
of social cognition.(46) Broadly, the disease can be divided into a pre-diagnostic and a diagnostic stage. 
During the pre-diagnostic stage, the changes that occur, involving alterations in personality, cognition 
and motor control(47) may remain unnoticed by the patient and family members. This stage is followed 
by the diagnostic stage during which patients suffer from incoordination, chorea, motor impersistence, 
and slowed saccadic eye movements.(5, 48)  
Studies reporting on symptomatic and protective treatments have been previously performed. 
Symptomatic treatment includes treating unusual movements, cognitive impairment, and psychiatric 
symptoms. In the case of Huntington’s disease, tetrabenazine (TBZ) is currently the only drug approved 
by the Food and Drug Administration (FDA) for the symptomatic treatment in Huntington’s disease. 
Vesicular monoamine transporter 2 concentrates monoamines into the vesicles, while TBZ reversibly 
inhibits this action, thus resulting in a more enhanced reduction of presynaptic dopamine than serotonin 
and norepinephrine.(6, 49, 50) The causes, symptoms, and conventional treatments of all three 
neurodegenerative diseases are summarized in Figure 2. 
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Figure 2 Causes, symptoms, and general treatments of neurodegenerative diseases 
 
3. BBB 
3.1 Structure 
The BBB is a specialized endothelial cell lining the intraluminal part of the brain capillaries, and 
splits the peripheral circulation from the CNS. The BBB is present to maintain a constant internal 
environment of the brain. Astrocytes, neurons, pericytes, and extracellular matrix are the other 
components of the BBB (Figure 3).(51) Polar solute movement is prevented across the cerebral 
endothelium due to the lack of aqueous pathways and tight continuous circumferential junctions 
present between cells.(52) The BBB enables the brain to maintain homeostasis and an unchanging 
environment while protecting the underlying brain cells. It also protects the brain from the entry of 
potentially toxic substances. Even during early development of newborns, the BBB provides the brain 
with a particular internal environment that helps neurons connect and grow.(53) However, the brain is 
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not totally inaccessible because of the barrier(54), and endothelial cells use several specific transport 
systems to enable the access of ample amounts of nutrients across the BBB.(52)  
 
Figure 3 Capillary structures of the BBB 
 
Our understanding of the BBB and how it functions have significantly improved after researchers 
have studied it on a cellular, metabolic, kinetic, and molecular level. Substances that may be toxic to the 
brain must be excluded from it and eliminated via the blood. This process is also dependent on the BBB 
mechanisms. The luminal surface of the capillary endothelial cells contain P-glycoprotein, which acts as 
an efflux pump and restricts cytotoxic drugs from accumulating.(55) Carrier mediated transport is the 
mechanism by which nutrients are supplied to the brain via the capillary endothelial luminal and the 
abluminal membranes.(56) The abluminal membrane of the endothelial cells is in connection with the 
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brain extracellular fluid, while the luminal membrane of the endothelial cells is with the blood 
component.(55) Glucose is transported to the brain with the help of a facilitated carrier of endothelial 
cells known as glucose transporter 1 (GLUT-1).(57) There are several transporters present to get amino 
acids across the BBB. System-L, an energy dependent transporter, transports valine, histidine, 
methionine, tyrosine, and phenylalanine to the brain, and can be found on both the luminal and 
abluminal membranes. Few neutral amino acids, namely alanine, serine, and cysteine, are transported 
by the Alanine/serine/cysteine (ASC) transporter. Figure 4 illustrates the main transport systems that 
facilitate the movement across the BBB. 
 
Figure 4 Transport pathways of endothelial cells in the BBB 
 
BBB defects can cause brain edema, auto-immunity, and several other disorders of the human 
body.(58) Several methods to overcome the BBB have been investigated and include the use of 
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antibodies,(59) liposomes,(60) nanoparticles, chimeric peptides, biochemical opening,(61) and osmotic 
opening of tight junctions, thus, strategically facilitating the brain drug delivery.(62, 63) 
3.2 Drug Passage across the BBB  
The BBB prevents the transport of all molecules except the ones that are small enough in size. This 
becomes a major problem for the treatment of brain disorders such as APHD, and brain cancers. Agents 
that are difficult to transport across the BBB include CNS active drugs, such as antineoplastic agents, 
neuropeptides, and antibiotics. Specialized transport systems are generally required even for the uptake 
of molecules that are relatively small such as amino acids and glucose by the brain.(58) The BBB is a part 
of the human body that remains least accessible to active pharmacological molecules. Although 
effective for the treatment of neurodegenerative diseases, conventional methods are much below the 
levels of optimum efficacy. Therefore, there is a need to develop therapeutic alternatives.(29) 
The endothelial cells of the BBB are equipped with lipophilic membranes. Thus, substances that must 
pass into the CNS must move from the hydrophilic environment of the blood to the hydrophobic 
environment of the endothelial cells. In addition, drugs can pass through small pores that are filled with 
water or through the cellular channels. Molecular size, drug lipophilicity, drug ionization, and plasma 
protein binding are drug properties that influence this process.(64) Studies have shown that lipid-soluble 
molecules with a low molecular weight around 400–600 Da are generally transported across the 
BBB.(65) 
Free drugs can be delivered through the BBB by different methods including physiologically based, 
pharmacologically based, and invasive methods.(66) Invasive methods include BBB disruption, intra-
ventricular drug infusion, and cerebral implants. Disruption of the BBB can be induced by osmotic or 
biochemical means. Intra-cerebral implants can alter the BBB permeability.(65) Osmotic BBB opening or 
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the application of biologically active agents such as bradykinin and histamine are other widely used 
techniques. 
4. Facilitated drug delivery through the BBB 
Disorders of the brain that are caused by the absence of peptides or hormones can be treated by 
administering those elements in a controlled manner. Controlled administration is an approach that can 
be used to treat common neurodegenerative disorders. However, for oral administration, there are very 
few stable small molecules that can act on neurons. The problem lies in the fact that proteolytic 
enzymes can easily degrade peptide drugs and result in the inaccessibility of the drugs to the site of 
action.(44) To overcome these problems, different methods are used to help the drug delivery across 
the BBB. More details are discussed below. 
4.1 Lipidization  
Lipidization of a molecule by surrounding it with a layer of lipids can improve the lipophilicity of a 
hydrophilic substance, which in turn improves its chances of penetrating the BBB. A hydrogen bond 
forming a polar functional group can be replaced by an apolar functional group, which does not form 
any hydrogen bonds with water. Codeine and heroin formation by O-methylation and O-acetylation of 
morphine, respectively, are classical lipidization techniques. When two hydrogen bonds are removed 
during the formation of codeine or O-methylation of morphine, the permeability of the BBB increases by 
ten folds of its baseline value.(67) It would be an extra advantage if the lipidization process is reversible 
and is converted back to the original molecule once the drug reaches the brain.(65) Paying attention to 
the efflux mechanisms of the drugs is of great importance. With respect to morphine, the brain-to-blood 
efflux rate is at the same slow pace as the blood-to-brain entry. The retention time, required for the 
conversion of the pro-drug to the drug, enables the retention of the drug in the brain. Lipidization can 
also be attained by the formation of fatty acids or cholesterol following the attachment of free fatty acyl 
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or cholesterol esters. Intravenous injections of these drugs exhibit better passage across the BBB, but 
may not be successful if administered orally.(68) The reason is that once fatty acyl or cholesterol esters 
is absorbed orally, it merges into lipoproteins resulting in a reduction in the ability to cross the BBB in 
comparison to free cholesterol.  
4.2 Disruption of the BBB 
Disruption of the BBB is another method by which molecules can cross the barrier. Some causes of 
disruption include hypertension, CNS tumors, seizures, and exposure to radiation.(55) The objective of 
disrupting the barrier is to either create a para-cellular transportation route across the endothelium or 
to create a trans-cellular pathway through the endothelium. Infusion of a hypertonic solution can 
disrupt the BBB. This can also be induced using angiotensin, bradykinin, or other biologically active 
agents that might be involved in controlling the behavior of the BBB.(55) 
As mentioned above, osmotic opening is one of the most common techniques used to pass through 
the BBB. Mannitol is usually the hypertonic solution that is infused into the carotid artery. By this 
method, large molecules can enter the CNS. One reason why this works may be because the para-
cellular pathways are physically opened due to the endothelial cells shrinking when in contact with the 
osmotic agent.(52) Osmotic disruption along with the infusion of drugs has been helpful in the 
treatment disorders related to the CNS such as brain cancer. Patients who received this treatment did 
not show any significant side effects and demonstrated an improvement in their survival time.(69) The 
only problem associated with this procedure is the inability to predict the long term neurological effects 
on the brain. Few cases were reported to have seizures following this procedure.(70) 
Radiation has been known as a cancer therapy method. More than that, it can disrupt BBB and 
facilitate the agent delivery to the brain.(71) It was shown that radiation can change the tight junction 
structure that results in the higher size dependent permeability of BBB both paracellularly and 
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transcellularly.(72) BBB disruption with 60 Gy radiation has been confirmed.(73) The brain necrosis or 
delayed necrosis after months or years are considered as the major shortcoming of radiation. To solve 
for this problem scientists tried to optimize the dosage of radiation.(74) Reinhold believed that the 
optimal dose of 20 to 25 Gy radiation leads to more diffusion alterations.(75) 
Focused ultrasound (FUS) is another method that can noninvasively help drug delivery to BBB.(76) 
Ultrasound can locally and selectively disrupt BBB with considerable damage to the brain tissue.(77) A 
circulating agent containing gas bubbles has been added to FUS that makes the BBB disruption 
reversible.(78) One of the major disadvantages of this method is the ultrasound attenuation by bone 
tissue of the skull followed by a wave distortion. Thus, an acoustic window should be designed using 
craniotomy.(77) To overcome this problem, FUS has been combined with imaging technologies like CT 
scans, MR imaging (MRI), and MR temperature imaging (MRTI) to control the heating and wave 
distortion related to FUS prevent craniotomy.(79, 80)  
4.3 Penetrating the BBB via nanomaterials 
Nanomaterials are materials with dimensions between a few to a hundred nanometers. The role of 
nanomaterials in medicine today is immense because their particle size is comparable to the size of 
proteins, nucleic acid, and antibodies. They also have a surface-to-mass ratio that is much higher than 
that of other particles. These biomimetic features together with their quantum properties, ability to 
carry and absorb other substances, and biodegradability make nanomaterials the most potent tools in 
modern medicine.(81) In neuroscience, the interaction with neurons at a molecular level is regarded as 
one of the main roles of nanomaterials. They also can be used to overcome the biggest obstacle in 
delivering drugs to the brain caused by the BBB.(82) Ideally, nanomaterials containing drugs are 
administered systemically to the patient, enabling them to cross the BBB and release drugs into the 
brain cells. This procedure could be very challenging and multidisciplinary solutions from different fields 
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such as engineering, medicine, chemistry, nanotechnology, pharmacology, and physiology are 
required.(83) With the advances in these areas, nanomaterials are not only used to serve as vectors to 
transport drugs across the BBB but researchers are also looking at multifunctional nanoparticles to help 
in the detection, treatment, and monitoring of brain diseases.(84) The application of nanotechnology to 
the field of medicine and health care is known as nanomedicine. Nanomedicine has the potential of 
significantly improving and changing the face of drug delivery, medical imaging, tissue regeneration, 
faster diagnoses, and other medical treatments.(85) There is a significantly lower amount of risks 
involved in using nanomaterials when compared to conventional methods used to treat brain diseases. 
Biodegradability and reduced toxicity to peripheral organs are added advantages of using nanomaterials 
for therapeutic purposes.(86)  
Penetration of drugs into the brain via nanocarriers can be achieved through different delivery 
systems such as carrier-mediated transport, chemical drug delivery systems, receptor mediated 
transport, active drug delivery systems, and endocytosis.(87) Loading nanoparticles with drugs can be 
done by different methods including covalent linkage, encapsulation, and adsorption.(88-90) 
Nanomaterials are considered the future of brain drug delivery to tackle neurodegenerative diseases 
because they are comparatively less toxic, more biocompatible, stable, biodegradable, and have the 
potency of drug delivery to the CNS by crossing the BBB.(91)  
Nanomaterial drug delivery systems are not only used as the treatment of neurodegenerative 
diseases and brain cancers but also for a better brain delivery of antiretroviral drugs, which are required 
for the treatment of patients infected with the human immunodeficiency virus. During the early stages 
of the infection, the virus enters the CNS. As a result, an independent viral reservoir is formed after 
being able to replicate actively in the brain compartment, thus causing drug resistance, complications, 
and infection. Several antiretroviral drugs available today are unable to overcome the BBB. Previous 
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studies have demonstrated that the concentration of the drug in the brain could be significantly 
elevated with the help of liposomes, SLN, micelles, and polymeric nanoparticles. Thus, the human 
immunodeficiency virus loaded in the brain could be significantly reduced by increasing the 
bioavailability of antiretroviral drugs through nanomaterial drug delivery systems.(92) 
Nanomaterial drug delivery systems can spare healthy cells by modifying nanomaterials to target 
diseased or abnormal cells selectively. In one particular study, a group of researchers used polylactic co-
glycolic acid (PEG)-coated hexadecyl cyanoacrylate nanoparticles to encapsulate an antineoplastic drug 
against glioma.(93) This method was proposed as an alternative for chemotherapy. Authors used 
spectroscopy, atomic mass microscopy, and other physical and chemical characterization methods to 
prove that the drug was efficiently loaded onto the nanoparticles. They also demonstrated the control 
of the drug release kinetics into the cells. Moreover, PEG-coated nanoparticles exhibited higher 
accumulation and diffusion/convection through the leaky BBB and a higher affinity to the normal BBB 
compared with the control sample due to its long circulating properties in Fischer rats bearing 
gliosarcoma.(93) In another study, rats were injected systemically with superparamagnetic SLN, which 
were made from microemulsions of solidified oil nanodroplets containing iron oxide and used as 
detection agents for MRI contrast.(94) After injection, the lipid nanoparticles exhibited a slower 
clearance and gathered in the brain after overcoming the BBB.(94) 
The exact mechanism by which nanomaterials can cross the BBB is not fully understood. However, 
several possibilities have been suggested. The most probable mechanism may be through endocytosis 
by endothelial cells that line the brain capillaries. Once the particles are taken up by the endothelial 
cells, they are released inside the brain possibly through transcytosis. Tight junction modulation or P-
glycoprotein inhibition may be the other processes by which nanomaterials cross the BBB. Furthermore, 
it is plausible that these processes occur in parallel.(95) 
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Surface modification is another method to enable drug-loaded nanoparticles to overcome the BBB. 
Surface modification can be induced by conjugating the drug-loaded nanoparticles with antibodies that 
are specific to the brain. Subsequently, the specific ligand recognizes the conjugate and allows the 
nanoparticles to pass through the BBB. However, the biggest hurdle here lies in the fact that it is very 
difficult to find specific ligands for the target tissue.(96) Specificity can also be achieved by coating the 
loaded nanoparticles with different surfactants.(95, 97) The ability for a surfactant to be efficient at 
targeting depends on its physicochemical and biochemical properties. Poloxamer 188 (F68) is one such 
surfactant that can improve the permeability of drug-loaded nanoparticles to the brain significantly. For 
example, it was obtained that Poloxamer 188 can enhance drug delivery of polybutylcyanoacrylate and     
poly(lactide-co-glycolide) (PLGA) nanoparticles loaded with drugs into the rat brain.(98, 99)  
Figure 5 illustrates the different types of nanomaterials that have been used to treat 
neurodegenerative diseases. 
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Figure 5 Available forms of nanoparticles that are used in the treatment of neurodegenerative diseases 
 
4.3.1 Nanoparticles  
Polymeric nanoparticles have been intensively investigated in medicine because of their 
biocompatibility, biodegradation, and low toxicity.(100-102) However, one obstacle in utilizing 
polymeric nanoparticles for drug delivery is engineering them into target-specific and stable systems. 
The role of the drug delivery system with respect to targeting does not end once it has entered the 
brain; it needs to have the ability to release the drug selectively to tissues or cells that are affected by 
the neurodegenerative disorder.(103) To date, only a few cases of polymeric nanoparticles using 
selective strategies have succeeded clinically.(104)  
One of the most commonly used polymeric nanoparticles in nanomedicine is PLGA,(105, 106) which 
has been approved by the FDA and the European Medicine Agency (EMA). It is well known for its high 
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biodegradability, which is essential in drug delivery systems. Yadav et al. studied the effect of PLGA 
nanoparticle size on biodistribution and blood clearance.(107) They used PLGA nanoparticles loaded 
with etoposide, and the size of the nanoparticles ranged between 100 nm and 160 nm. The results 
showed that for long-term circulation without any surface modification, the 100 nm nanoparticles 
worked best because they could escape the liver metabolism.(107) This and several other studies 
suggest that PLGA is a promising candidate for enhancing therapeutic delivery into the CNS.(108-120) 
However, PLGA degrades by bulk erosion, which can lead to premature exposure of the therapeutic 
to a degradative environment.(121) Additionally, the therapeutic release profile of PLGA nanoparticles is 
difficult to control due to the penetration of water into the bulk.(122) These issues could potentially be 
solved using surface-eroding polyanhydride nanoparticles. Also FDA-approved, these nanoparticles are 
biocompatible and induce low inflammatory responses in vivo.(123-129) Because they erode from the 
surface, the release timescale can be precisely tuned by altering the nanoparticle chemistry to deliver 
therapeutics at the right time and therefore enhance therapeutic efficacy while also lowering the 
effective dose.(130-132) Importantly, they are also small enough, around 300-400 nm, to be efficiently 
internalized by many different cell types.(133-135) Overall, polymeric nanoparticles are the most 
preferred nanocarriers as they are easy to fabricate, stable, safe, and exhibit better controlled release of 
drugs. However, one of the biggest challenges for the therapeutic use of polymeric nanoparticles is the 
scale-up procedure keeping in mind the cost factor.(109) 
4.3.2 Nanogels and nanosuspensions  
Polymers that form crosslinked networks are able to combine ionic and nonionic polymeric chains 
to form nanogels.(21, 136) Natural polymeric materials have been broadly applied in tissue engineering 
and drug delivery.(137-145) Nanogels have the ability to carry oligonucleotides, DNA, proteins, low 
molecular weight drugs, and other small molecules after swelling up in water. Vinogradove et al. studied 
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the passage of crosslinked nanogels encapsulating oligonucleotides across the BBB in vivo.(20, 146) Their 
results indicated that the uptake of nanogel in the spleen and liver was decreased, while it was 
increased in the brain.(20, 146) Nanosuspensions are another type of nanomaterials that can be 
potentially used for delivering molecules across the BBB. They can carry drug particles that are 
crystalline in nature and stabilized by nonionic surfactants or lipid mixtures.(147) Nanosuspensions are 
known for their good drug loading capacity and simplicity. Thus, they can be potentially used to deliver 
several drugs across the BBB to the CNS.(20, 147, 148) 
4.3.3 Dendrimers  
Dendrimers are nanoscaled macromolecules that have repetitive branching.(149) The functional 
groups at the exterior of dendrimers are largely responsible for trapping drug molecules to be 
transported into the brain.(150) Dendrimers can be used to overcome the difficulties that other drug 
delivery systems experience for brain delivery, such as bad permeability across the BBB, resistance 
development to drugs, and limited selectivity to diseased cells. Dendrimers can be used to target the 
brain, which can be achieved because of their structure, small nanometric size range, and functional 
advantages. Dendrimers have many surface groups that can be exploited and used to conjugate 
multifunctional ligands. Another advantage is that drugs can be entrapped in the spaces present in 
dendrimers, thus enabling the protection of the drugs from the external environment.(151) 
The passage of polyether-copolyester dendrimers crossing the BBB has been studied previously by 
labeling dendrimers with rhodamine B. At high concentrations, the brain vascular endothelial cells were 
saturated with the polyether-copolyester dendrimers. Furthermore, the dendrimers were inhibited 
fractionally by clathrin and caveolin. Their results highlighted the influence of the architecture of 
dendrimers on the crossing of the BBB.(150, 151)  
4.3.4 Solid lipid nanoparticles (SLN) 
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Many lipid-based nanocarriers have been investigated and proved to have great potential in drug 
delivery to the brain. These lipid-based nanomaterials are both biocompatible and biodegradable. 
Lipophilic materials work very well at targeting and crossing the BBB.(92) Compared to other 
nanocarriers, SLN are relatively new (Figure 6A,B),(152, 153) stable, and can be produced by multiple 
methods such as solvent injection, microemulsification, solvent emulsification, and high pressure 
homogenization. They are essentially comprised of an aqueous surfactant that includes dispersed 
melted lipid.(150) The target drug to be transported to the brain is usually present in the hydrophobic 
core of the SLN.(154) Furthermore, drug release from these nanoparticles can be controlled and can last 
for months due to their excellent drug entrapment ability and stability (Figure 6C).(155) 
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Figure 6 (A) polymer-lipid nanoparticle (PLN) formation. D
+
 represents the water-soluble cationic drug molecule 
and curved line shows the anionic polymer chain. The charges of the two molecule are neutralized and results in 
the PLN formation.(152) (B) Transmission electron microscopy (TEM) of blank Solid lipid nanoparticles (SLN) and 
Actarit-loaded SLN (right).(153) (C) Scanning electron microscopy (SEM) of dry powder inhalation (DPI) system of 
SLN loaded with insulin.(155) (D) Cytotoxicity comparison of the Dynasan-SLN (□), Compritol-SLN (●), 
polyhexylcyanoacrylate (+), and polymethylcyanoacrylate (Δ) nanoparticles in contact with human promyelotic 
HL60 cell lines. Cells showed higher viability exposed to SLN nanoparticles compared to the reference drug 
carriers.(156)  
The boiling points of SLN are a little higher than the body temperature; hence, once these 
nanoparticles enter the body, they turn into solid particles. It has been previously demonstrated that 
SLN exhibit low non-specific cell toxicity (Figure 6D).(156) In a lipophilic environment, SLN become 
immobilized, which protects them from degradation. In another study, SLN loaded with nitrendipine as 
the target drug were fabricated using triglycerides, emulsifiers, and charge modifiers.(157) Compared to 
the nitrendipine suspension, which presented an elevated drug concentration in the brain over 3 h, the 
nitrendipine-loaded SLN presented a high drug concentration for double the amount of time.(157) Thus, 
SLN present a possible drug delivery system to treat neurodegenerative diseases.(150) 
4.3.5 Nanoemulsions 
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The dimensions of nanoemulsions range between 20–200 nm (Figure 7A).(158) This oil in water 
formulation consists of an oil phase in dispersed droplets, and also has surfactants and co-surfactants 
that stabilize it. Nanoemulsions are especially suitable for highly lipophilic drugs that need to be 
transported to the brain,(92) and can be prepared either by high or low energy methods. The oil 
component of a nanoemulsion is of great importance in the brain drug delivery process. nanoemulsions 
have been proven to have selectivity in uptake of  needed polyunsaturated and omega-6 fatty acids, 
pinolenic acid, and linoleinic acid.(150) Edmond et al. demonstrated that oleic acid, which has one cis-
double bond, was not transported across the BBB, while linoleic acid, having two cis-double bonds and 
18 monocarboxylic acids, was successfully transported to the brain.(159) Therefore, there is a lot of 
therapeutic potential in this type of lipid nanocarriers.  
 
Figure 7 (A) Nanoemulsion (left) and Macroemulsion (right).(158) (B) The effect of liposome composition on cell 
transfection. Cholesterol in a cationic liposome formulation, such as DOTAP, acts as a helper lipid to transfect C6 
cells, Hippocampal neurons, and Cortical neurons. DOTAP stands for 1,2-dioleoyl-3-trimethylammonium-propane 
and DOPE stands for L-α-dioleoyl-phosphatidylethanolamine.(160) 
 
4.3.6 Liposomes 
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Liposomes are the most commonly studied and used nanocarriers.(161) Liposomes are vesicles 
with an artificial phospholipid bilayer. Many studies have demonstrated successful drug delivery to the 
brain via liposomes, namely cisplatin for brain tumors, phenytoin for epilepsy, and citicoline for cerebral 
ischemia.(162-164) 
Normally, BBB prevents the passage of hydrophilic and drugs of high molecular weight such as 
calcitonin. In a previous study, calcitonin was encapsulated in liposomes and its availability in the CNS 
was studied in vivo.(60) The results indicated that calcitonin encapsulated in sulfatide liposomes could 
cross the BBB and were detectable in the CNS. The areas where biodistribution was observed included 
the hypothalamus, brain stem, spinal cord, and striatum.(60) In some instances, cholesterol, which is a 
part of cell membranes, is included in the liposomal constitution, which reduces the permeability of the 
liposome through BBB and increases the phospholipid bilayers stability .(150, 165, 166)  
Cationic liposomes are other types of liposomes frequently studied and used. Genetic drugs can be 
entrapped in cationic liposomes, thus enabling the protection of the genetic drugs from the extracellular 
environment and their delivery to the target tissues and cells. The positively charged liposomes and the 
negatively charged genetic drugs exhibit instantaneous electrostatic interactions. Due to these 
reactions, cationic liposomes facilitate the transfection of nucleic acids and enable the condensation of 
nucleic acids efficiently. Unlike the liposomal structures, the cationic liposomes are actually hexagonal 
structures known as lipoplexes because of the electrostatic interactions.(167) Cationic liposomes that 
are available for the purpose of gene transfer include [(2,3-dioleyloxy) propyl] -N,N,N-trimethyl-
ammonium chloride (DOTMA) and 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP). Their 
transfection efficacy can be improved by supplementing them with dioleoylphosphatidylethanolamine 
(DOPE). Addition of cholesterol was another way to improve the transfection efficacy and the stability of 
liposomes when they were around the serum (Figure 7B).(160)  
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4.3.7 Micelles  
When dispersed in a liquid phase, 50–100 amphiphilic molecules aggregate together to form a 
micelle.(168) These amphiphilic molecules contain a head with hydrophilic properties and a tail with 
hydrophobic properties. When a molecule is designed in this way, it enables hydrophobic drugs to be 
stored at the center or core of the micelles. Generally, the size of micelles is in the order of 5 to 20 nm in 
diameter.(92) The ability of micelles to solubilize drugs in their cores and their small sizes make them 
good carriers for brain drug delivery. Pluronic P85 has been previously shown to affect the permeability 
of micelles through the BBB using the bovine brain micro vessel endothelial cell monolayer model. 
Pluronic micelles significantly enhanced the transport of drugs across the BBB. The study showed that 
the permeability of the drug was increased by a 19-fold.(169, 170)  
4.3.8 Improving nanocarrier delivery using targeting strategies 
The central hurdle for delivery of any of the aforementioned nanocarrier technologies into the 
brain is crossing the BBB.(103) Recent reviews have investigated ways to design nanocarriers to cross 
the BBB more efficiently by using targeting methods.(171-173) Mullis et al. details the importance of 
targeting strategies for enabling delivery across the BBB, and suggests several ligands used in recent 
studies that may be utilized for enhancing nanocarrier-mediated brain delivery.(171) These ligands can 
improve BBB transcytosis of the nanocarrier using one of three methods, including receptor, adsorptive, 
and cell-mediated transcytosis.(171)  This article also emphasizes the importance in enabling 
nanocarrier targeting downstream of the BBB for optimized therapeutic efficacy.(171) One way to do 
this could be by designing a nanocarrier that presents ligands temporally.(171) Moreover, while the 
choice of nanocarrier is important for delivery of neurodegenerative disease therapeutics, so is the 
choice in targeting ligand for that nanocarrier. 
4.4 Conclusions 
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Overall, nanotechnology can be used to overcome diagnostic and therapeutic challenges that are 
associated with neurodegenerative diseases. Previous studies have demonstrated that nanoparticles can 
cross the BBB both in vitro and in vivo.(174, 175) This proves that drug delivery systems using 
nanomaterials can enable and improve brain drug delivery and neurotherapeutic interventions.(20, 176) 
5. Nanocarriers in the treatment of neurodegenerative diseases 
5.1 Nanocarriers in Alzheimer’s disease 
The main reason of neurodegeneration in Alzheimer’s disease is the accumulation of plaques or 
amyloid beta protein in the temporal and parietal lobes, which causes changes in cognition, memory 
loss, hallucination, depression, aggression, agitation, and anger.(177) The majority of the drugs currently 
available are acetylcholinesterase inhibitors, which delay the breakdown of acetylcholine in the initial 
stages of the disease.(178) Like the therapies for other neurodegenerative disorders, the biggest 
obstacle in the treatment of Alzheimer’s disease is the inability of molecules to cross the BBB. 
Nanomaterials can either be used to encapsulate drugs and biologically active agents to combat the 
disease by targeted delivery, or to reduce the toxicity of plaques by preventing their accumulation.  
Clioquinol (5-chloro-7-iodo-8-hydroxyquinoline) is a derivative of quinolone, which is able to 
solubilize the plaques that accumulate in the neocortex in the extracellular synaptic spaces at the onset 
of Alzheimer’s disease in humans. Clioquinol can also solubilize plaques in transgenic mice models of 
Alzheimer’s disease.(179, 180) Nanomaterials can be used as a carrier to transport clioquinol across the 
BBB to treat Alzheimer’s disease. For example, n-butyl-cyanoacrylate nanoparticles can be used to 
encapsulate clioquinol for delivery through the BBB.(180) Donepezil is a cholinesterase inhibitor used 
therapeutically in Alzheimer’s disease, which is normally unable to cross the BBB. Bhavna et al.110 
applied PLGA nanoparticles about 83.24 nm to 96.10 nm in size as nanocarriers for donepezil delivery to 
the brain. Their results demonstrated successful uptake of the nanoparticles in the brain, and the 
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pharmacokinetics revealed a burst release at the beginning, which was followed by a slow release in the 
brain.(181) It has been previously reported that excessive oxidative stress in the brain is involved in 
neuronal damage and death in patients with Alzheimer’s disease. Fullerenols, which are well studied 
antioxidants (Figure 8A), can be potentially used to prevent the formation of amyloid plaques in 
Alzheimer’s disease.(182, 183)  
Early diagnosis of Alzheimer’s disease is critical to prevent excessive neuronal damage and 
unnecessary symptoms by starting the treatment at an early stage. Nanotechnology can be used as a 
tool to help in the early diagnosis of the disease.(184) There are mainly two ways by which Alzheimer’s 
disease can be diagnosed early. The first method utilizes nanoparticles that are marked with fluorescent 
probes and the second method utilizes magnetic nanoparticles that can be detected by magnetic 
resonance imaging. Iron oxide nanoparticles is an example of nanoparticles that are used in magnetic 
resonance imaging as contrast agents. Monocrystalline iron oxide nanoparticles have been successfully 
applied to target and envision plaques formed as a result of Alzheimer’s disease.(185) The advantages of 
utilizing iron oxide nanoparticles are large surface area and low toxicity. The FDA has approved the use 
of these nanoparticles for magnetic resonance imaging of the liver.(184, 186) Furthermore, gold 
nanoparticles are a good choice for the detection of beta-amyloid plaques and monitoring their 
alteration.(187) Future in vitro and in vivo studies are still warranted, especially regarding toxicity, to 
evaluate their safe use in the diagnosis of Alzheimer’s disease.(184) As a hydrophilic fluorescent marker, 
Thioflavin-T can be used to detect beta-amyloid plaques. However, the problem with this marker is its 
limited passage across the BBB. In contrast, encapsulating Thioflavin-T in butyl-cyanoacrylate 
nanoparticles significantly improves their effective transport across the BBB. The accumulation of 
nanoparticles in the cytoplasm of granule cells and the drug release are illustrated in Figure 8B, thus 
advancing this method as a promising treatment option in Alzheimer’s disease.(188)  
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Figure 8 (A) Fullerenol structure.(182) (B) Accumulation of core shell latex particles loaded with Thioflavin-T in the 
cytoplasm of granule cell. The surrounding material represents the Thioflavin-T released from particles. Scale bar 
represents 1 µm.(188) (C) Rivastigmine concentration in various organs after intravenous injection to rat models. 
Riv represents administration on free Rivastigmine. Riv-NP represents poly(n-butylcyanoacrylate) nanoparticle 
encapsulating Rivastigmine. Riv-NP-PS 80 represents nanoparticles encapsulating Rivastigmine coating with 1% 
polysorbate 80.(189) (D) Tacrine concentration in various organs after intravenous injection to rat models. Tac 
represents the administration of free Tacrine. Tac-NP represents poly(n-butylcyanoacrylate) nanoparticle 
encapsulating Tacrine. Tac-NP-PS 80 represents nanoparticles encapsulating Tacrine coating with 1% polysorbate 
80.(190) (E) Resonance units of liposomes over time that represent their preferential binding to β-amyloid 
monomers, oligomers, or fibrils. All liposomes are constituted of sphingomyelin from bovine brain (Sm) and 
cholesterol (Chol) (Sm:Chol 1:1). Upper figures have dimyristoylphosphatidic acid (PA) as the third component to 
combine with Sm and Chol. Lower figures have cardiolipin (CL) as the third component to combine with Sm and 
Chol. Left figures have 5 molar % and right figures have 20 molar % of the third component.(191) 
 
Another treatment method for Alzheimer’s disease is improving the cholinergic neurotransmission. 
Acetylcholinesterase is an enzyme accountable for the breakdown of acetylcholine; thus, 
acetylcholinesterase inhibitors can be utilized to inhibit the acetylcholine breakdown, which in turn 
increases the action levels of acetylcholine. Rivastigmine is a non-competitive and reversible 
acetylcholinesterase inhibitor that was approved by the FDA for the treatment of Alzheimer’s disease in 
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2000.(184) Similarly to other agents, nanocarriers can be applied for the rivastigmine transportation 
through the BBB into the CNS. In a previous study, rivastigmine was encapsulated in poly n-
butylcyanoacrylate nanoparticles with coating of polysorbate. Subsequently to intravenous injection, the 
amount of rivastigmine increased by 3.8 folds in the rat brain (Figure 8C). In another study using tacrine, 
which is another acetylcholinesterase inhibitor, drug uptake was increased by 4 times in the mouse 
brain (Figure 8D).(189, 190) 
Oxidative damage promoted by metals such as iron, zinc, copper, and aluminum is a cause of 
Alzheimer’s disease. Since these metals create an environment that supports oxidation, the use of 
chelators to reduce the metals in the brain may be an option for the disease treatment. Studies have 
shown that nanoparticles attached to chelators could cross the BBB.(178) D-Penicillamine is a copper 
chelator approved by the FDA with the ability to treat diseases such as Wilson’s disease and rheumatoid 
arthritis.(35) However, the high hydrophilicity of D-Penicillamine prevents its entry through the 
BBB.(192) Therefore, 1,2 Dioleoyl-sn-glycero-3-phosphoethanolamine-N-(4-[p-maleimidophenyl]-
butyramide) (sodium salt) (MPB-PE) containing nanoparticles and 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-(3-[2-pyridyldithio]-Propionate) (sodium salt) (PDP-PE) containing 
nanoparticles were coupled covalently by disulfide bonds to D-penicillamine. Reducing agent 
dithiothreitol promoted the D-penicillamine release from the nanoparticles, thus demonstrating the 
successful transport of D-penicillamine across the BBB via nanoparticles. Therefore, D-penicillamine can 
be used to reduce the amount of metal ions that are known to promote the beta-amyloid deposition in 
patients with Alzheimer’s disease. This nanocarrier system has been reported not to affect the integrity 
of the BBB.(35, 192) 
The ferulic acid is a both an antioxidative and anti-inflammatory in nature. Studies on ferulic acid 
loaded in SLN have indicated that it can prevent cell death by sparing neurons of oxidative stress.(184, 
193, 194) Gobi et al. used SLN and liposomes loaded with phosphatidic acid cardiolipins for the 
Page 31 of 55 Nanoscale
N
an
os
ca
le
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
27
 A
ug
us
t 2
01
8.
 D
ow
nl
oa
de
d 
by
 Io
w
a 
St
at
e 
U
ni
ve
rs
ity
 o
n 
9/
4/
20
18
 6
:2
8:
40
 P
M
.
View Article Online
DOI: 10.1039/C8NR04073G
 32 / 54 
 
treatment of Alzheimer’s disease by targeting the beta amyloid plaques.(191) The average size of the 
nanoparticles used was between 76 nm and 145 nm. Surface plasmon resonance studies were 
conducted using these nanoparticles and indicated a high affinity towards the beta amyloid fibrils 
(Figure 8E).(184, 191) Dendrimers are nanosized materials that display a repeated pattern of branching. 
Chafekar et al. conducted studies using functionalized dendrimers to evaluate their effect on beta 
amyloid plaques. Their results indicated that the nanoparticles did prevent the accumulation of the 
plaques, but rather promoted the disintegration of aggregated amyloid plaques.(184, 195) 
5.2 Nanomaterials in Parkinson’s disease  
Parkinson’s disease manifests itself after a series of events at the molecular and cellular level, 
which lead to biochemical and neurological disturbances.(196) Nanomaterials can be used as a tool to 
advance the treatment of Parkinson’s disease via precise control of biological systems. For example, 
nanotechnology may greatly advance neuroprotection in Parkinson’s disease.(4, 197, 198) 
Polymeric nanoparticles are studied extensively to promote the drug delivery to the brain to treat 
Parkinson’s disease. The first polymeric nanoparticles crossing the BBB were the 
poly(butylcyanoacrylate) (PBCA) nanoparticles. Indeed, PBCA nanoparticles coating with polysorbate 80 
could cross the BBB and deliver drugs to the brain.(199) Polysorbate 80 coating supports the transport 
of PBCA into the brain through interacting with the BBB in a manner similar to that of low density 
lipoproteins.(109) Other polymers used so far included the poly (lactic acid) (PLA), poly (glycolic acid) 
(PGA), and PLGA, all of which were capable of crossing the BBB to treat Parkinson’s disease.(109, 200) 
Chitosan is a naturally occurring polymer with the ability to form nanoparticles to treat Parkinson’s 
disease. Researchers have shown that chitosan nanoparticles can be useful in delivering peptides and 
dopamine to the brain. Figure 9A depicts the dopamine concentration in the rat striatum after a single 
chitosan nanoparticle injection. As stated before, the symptoms of Parkinson’s disease are largely due to 
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the reduction in the levels of dopamine. Therefore, chitosan nanoparticles can be potentially used as 
carriers to transport dopamine to the CNS to treat Parkinson’s disease. (109, 201, 202)  
In terms of nanocarrier targeting strategies, several studies have examined using targeting ligands 
to further improve therapeutic efficacy of nanocarriers for Parkinson’s Disease treatments.(203, 204) 
For example, Hernando et al. investigated using transactivator of transcription peptide conjugated to a 
lipid carrier, and found that the efficacy of the encapsulated therapeutic, glial cell-derived neurotrophic 
factor, was improved.(203) In another study, Wen et al. conjugated a lectin derivative, Odorranalectin, 
to PLGA-based nanoparticles to improve delivery across the nose-brain barrier.(204) In both of these 
studies, overcoming the BBB was achieved by essentially bypassing it using intranasal delivery as the 
method of administration. 
Gene delivery to the CNS with the help of nanocarriers can potentially support the treatment of 
Parkinson’s disease. Gene delivery can be used to alter the capability of the brain to regenerate and 
improve compensatory mechanisms, and further treat other brain pathological processes.(198, 205) 
Neurotrophic factors are responsible for the growth and development of brain cells. A majority of the 
symptoms associated with Parkinson’s disease are associated with a reduction in the amount of 
dopamine production. Neurotrophic factors can boost brain cell survival and increase dopamine level. 
Thus, delivering genes that code for neurotrophic factors with the help of nanocarriers can potentially 
prevent brain cell death and mitigate the disease symptoms.(206, 207) 
Other nanomaterials applied in Parkinson’s disease include the use of fullerenols. Fullerenols are 
obtained from buckminsterfullerene (C60), which is known to prevent apoptosis, glutamate receptor 
action, and neuronal oxidation (Figure 9B).(208) Carbon nanotubes can be also used as wireless 
biosensors in the treatment of Parkinson’s disease. Carbon nanotubes arranged to form a carbon 
nanochip are able to keep track of dopamine level changes and to maintain it at a controlled level.  
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Figure 9 (A) The percent of dopamine in rat striatum in a 4-h time period. Single dosage (6–12 mg/kg) was injected. 
DA stands for dopamine. Vehicle = chitosan nano particles (CSNP). CSNP stands for chitosan nanoparticles. *p < 
0.05, **p < 0.01, ***p < 0.001 versus respective vehicle; #p < 0.05, ##p < 0.01 versus respective DA/CSNPs (5) (6 
mg/kg). Arrow shows the administration time.(202) (B) Confocal microscopy of cortical astrocytes treated with 
vehicle (H2O) (upper) and C3 fullerene (the tris malonic acid C60 adducts) (lower). Superoxide-sensitive 
dihydroethidium (DHE) was used as the fluorescent compound and decreasing fluorescent in the sample 
containing C3 showed that C3 resulted in lower mitochondrial superoxide anion production.(208)  
 
5.3 Nanomaterials in Huntington’s disease 
Huntington’s disease is a genetic disorder featuring cognitive symptoms, motor symptoms, chorea, 
dementia, and psychosis. Almost 40% of the patients diagnosed with the disease suffer from depression, 
and the disease is often mistaken with schizophrenia because of their shared symptoms.(209) Similarly 
to Alzheimer’s disease and Parkinson’s disease, nanocarriers can be used as a tool to deliver drugs and 
therapeutics across the BBB to treat Huntington’s disease. 
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Free radicals in the brain are formed as a result of oxidation, and remain in the brain mainly due to 
poor anti-oxidant activity, thus leading to neuronal damage and death. Poor antioxidant defense in the 
brain can also cause neuronal death in the case of neurodegenerative diseases, such as Huntington’s 
disease. Hence, antioxidants can be used as therapeutics to prevent oxidative stress in Huntington’s 
disease.(182) Fullerenols, which are derivatives of fullerenes, are hydrophilic and able to clear 
surrounding free radicals; indeed, fullerenols are commonly referred to as radical sponges due to their 
ability to remove free radicals.(182) Their anti-oxidant nature and spherical, hollow shape make them 
ideal carriers for the treatment of Huntington’s disease. The anti-oxidant nature of fullerenols has been 
demonstrated repetitively. Jin et al. reported that fullerenols were effective in blocking glutamate 
receptors in an antagonistic nature and can therefore be used for neuroprotective applications (Figure 
10A).(210)  
The application of SLN have been investigated extensively for the treatment of neurodegenerative 
diseases and delivery of the drug to the CNS. SLN are lipidic nanocarriers, which enables them to move 
more readily across the BBB into the brain. Nitrendipine is a dihydropyridine calcium channel blocker 
that reduces the incidences of dementia in Huntington’s disease by a margin of 50% in a span of 2 
years,(211) thus exerting neuroprotective effects.(212) However, being hydrophilic in nature, 
nitrendipine cannot cross the BBB effectively. In one study that compared the uptake of nitrendipine 
when administered normally and when administered using SLN, nitrendipine was encapsulated in SLN 
made of a mixture of glycerides, namely, tripalmitin, trimyristin, and tristearin. The results indicated an 
increase in nitrendipine uptake by the brain when SLN were used ,(157) suggesting their potential use in 
the treatment of Huntington’s disease. In another study, modified cyclodextrin was used to encapsulate 
short-interfering RNA (siRNA) with the aim of decreasing the expression of mutant huntingtin (HTT) 
gene. This strategy resulted in the reduced expression of  HTT mRNA both in vivo and in vitro as well as a 
low cytotoxic effect (Figure 10B) (213, 214) Although a detailed description of the positive aspects of the 
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use of self-assembled chitosan nanomaterials in drug delivery was provided, there was no mention of 
any drawbacks using these systems, e.g., scale-up. For a critical review of the field, more effort is 
needed to present both the beneficial and unfavorable effects from different aspects. 
 
Figure 10 (A) Glutamate (Glu) receptors blocking of fullerenol. Glu induced free intracellular calcium is believed to 
be the reason for neurotoxicity. Cultures A-E all were treated with 50 µM fullerenol. Sample A contained no Glu, B-
E related to the 0.5, 1, 3, and 5 minutes after treatment with Glu, F contained no Glu and no fullerenol and G 
contained no fullerenol but, 0.25 mM of Glu. Comparison between G and E clearly showed the effect of fullerenol 
on free calcium decrease.(210) (B) The effect of short-interfering RNA (siRNA)-loaded modified cyclodextrin (CD) 
on the mutant Huntington (HTT) gene expression in a rat striatal cell line. Knockdown of HTT gene expression was 
obtained with PCR.(214) 
Table 1 summarizes some of the studies conducted using nanoparticles in the treatment or 
diagnosis of neurodegenerative diseases. 
Table 1. Nanoparticles used in neurodegenerative disease 
Disease Types of 
nanoparticles used 
for treatment 
Size range Advantages Surface 
modificati
on/Coatin
g 
References 
Alzheimer’s 
Disease 
SLN 93.20–99.12 
nm(194), 76–
145 nm(191) 
High affinity of SLN 
to beta amyloid 
fibrils 
 Picone et 
al(194), Gobi 
et al.(191) 
 Dendrimers 20–80 
nm(195) 
Regular and highly 
branched 
structures, size, 
and structural 
resemblance to 
protein molecules 
 Chafekar et 
al.(195) 
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PLGA1 nanoparticles 
 
83.24–96.10 
nm(181) 
Biocompatibility 
and 
biodegradability  
 
Polysorbat
e coating 
 
Bhavna et 
al.(181) 
 
 
 
PBCA2 
33.6–47.4 
nm(189) 
 
 
Ability to cross the 
BBB (BBB) 
efficiently 
 
Polysorbat
e coating 
Wilson et 
al.(189, 190), 
Roney et 
al.(180) 
 
 1,2-
(dimethoxymethano) 
fullerene 
 Inhibition of 
amyloid peptide 
aggregation at the 
first stages with a 
large inhibitory 
constant 
 Kim et 
al.(183) 
 MION3  Early detection of 
amyloid plaques 
 Wadghiri et 
al.(185) 
 Co@Pt nanoparticles 15 nm(187) Improved magnetic 
properties, high 
colloidal stability, 
early detection of 
Aβ plaque, and 
probe of protein 
self-assembly 
Au Choi et 
al.(187) 
 Thioflavin-T-
containing core-shell 
latex particles 
90 nm(188) Localization of 
nanoparticles 
intracellularly to 
prevent synthesis 
of Aβ plaques and 
extracellularly to 
prevent Aβ plaque 
formation 
 Hartig et 
al.(188) 
Parkinson’s 
Disease 
PLGA  Good 
biodegradability 
and ability to 
control the rate of 
biodegradability 
Polysorbat
e 80 
surface 
coating 
Patel et 
al.(109, 188) 
 Carbon Nanotubes  Light weight, high 
mechanical 
strength, and inert 
chemically 
 Modi et 
al.(20) 
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 Chitosan  67-147 
nm(202) 
Biodegradable, 
biocompatible, low 
toxicity, and good 
uptake of 
hydrophilic drugs 
and peptides 
Polysorbat
e 80 
coating 
Trapani et 
al.(202) Patel 
et al.(109), 
Mao et 
al.(215) 
 PBCA 118-179.2 
nm(216) 
Easy fabrication, 
ability to cross the 
BBB efficiently 
Non-ionic 
surfactant
- 
polysorbat
e 80 
Patel et 
al.(109), 
Olivier(199), 
Lin et 
al.(216) 
Huntington
’s Disease 
 
 
Fullerenols 
 
 
 
Hollow and 
spherical structure, 
anti-oxidant 
properties, and 
ability to remove 
free radicals- 
“radical sponge” 
 
 
 
Grebowski et 
al.(182), Jin 
et al.(210), 
Injac et 
al.(217) 
 
  
SLN 
[NDP-Nitrendipine] 
[TP-Tripalmitin] 
 
 
105.8–108.6 
nm(157) 
(NDP-TP-
DCP) 
106.7–110.5 
nm (NDP-TP-
SA) 
 
 
Increased 
bioavailability, 
good for controlled 
and targeted drug 
delivery, 
reproducibility, 
stability, and lower 
toxicity 
 
Surface 
charge 
modifiers-
dicetyl 
phosphate 
(DCP), 
stearylami
ne (SA). 
 
Manjunath 
et al.(157), 
Kaur et 
al.(154)  
 Β-Cyclodextrin 100–350 
nm(214) 
Huntingtin (HTT) 
gene silencing, 
favorable cell 
toxicity 
 Godinho et 
al.(214) 
1
 Poly(lactic-co-glycolic acid) 
2 
Poly(n-butylcyanoacrylate) 
3 
Monocrystalline iron oxide nanoparticles 
6. Conclusions and perspectives 
Based on a large body of literature, it is evident that nanocarriers represent the future of drug 
delivery to the CNS. The BBB is selective to the entry of limited molecules, which helps prevent the 
intrusion of harmful molecules into the CNS. However, this protective feature of the BBB is also the 
biggest hurdle in the delivery of drugs for the treatment of neurodegenerative diseases. Nanocarriers 
can cross the BBB and can thus be used as a tool for brain drug delivery. Inability of the drugs to cross 
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the BBB can be enhanced by their encapsulation inside the nanocarriers to facilitate their entry into the 
brain. This procedure is non-invasive and drugs trapped in nanocarriers can be administered 
intravenously. The main advantage of engineered nanoscale drug delivery systems is that the drug or 
the active component is not involved in the obstacles of transporting the drugs to the target area. Thus, 
nanocarriers can be engineered in the desirable way without involving or changing the drug.  
The main challenges for nanoparticles used for this purpose, especially when targeting the brain, 
are biodegradability, biocompatibility, and non-toxicity. Another limitation that needs to be overcome is 
the low encapsulation efficiency of some drugs. Non-biodegradable nanoparticles can accumulate in the 
brain and turn into toxic substances, thus resulting in complications. Due to the limited data available 
from in vivo and clinical studies regarding the use of nanoparticles for drug delivery into the CNS, 
potential toxic side effects are still unknown. Therefore, further research is still warranted to validate 
the potential therapeutic use of nanocarriers to treat neurodegenerative diseases. 
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Figure captions 
Figure 1. Overall scope of neurodegenerative diseases 
Figure 2. Causes, symptoms, and general treatments of neurodegenerative diseases 
Figure 3. Capillary structures of the BBB 
Figure 4. Transport pathways of endothelial cells in the BBB 
Figure 5. Available forms of nanoparticles that are used in the treatment of neurodegenerative diseases  
Figure 6. (A) polymer-lipid nanoparticle (PLN) formation. D+ represents the water-soluble cationic drug 
molecule and curved line shows the anionic polymer chain. The charges of the two molecule are 
neutralized and results in the PLN formation.(152) (B) Transmission electron microscopy (TEM) of blank 
Solid lipid nanoparticles (SLN) and Actarit-loaded SLN (right).(153) (C) Scanning electron microscopy 
(SEM) of dry powder inhalation (DPI) system of SLN loaded with insulin.(155) (D) Cytotoxicity 
comparison of the Dynasan-SLN (□), Compritol-SLN (●), polyhexylcyanoacrylate (+), and 
polymethylcyanoacrylate (Δ) nanoparticles in contact with human promyelotic HL60 cell lines. Cells 
showed higher viability exposed to SLN nanoparticles compared to the reference drug carriers.(156)  
Figure 7. (A) Nanoemulsion (left) and Macroemulsion (right).(158) (B) The effect of liposome 
composition on cell transfection. Cholesterol in a cationic liposome formulation, such as DOTAP, acts as 
a helper lipid to transfect C6 cells, Hippocampal neurons, and Cortical neurons. DOTAP stands for 1,2-
dioleoyl-3-trimethylammonium-propane and DOPE stands for L-α-dioleoyl-phosphatidylethanolamine. 
(160) 
Figure 8. (A) Fullerenol structure.(182) (B) Accumulation of core shell latex particles loaded with 
Thioflavin-T in the cytoplasm of granule cell. The surrounding material represents the Thioflavin-T 
released from particles. Scale bar represents 1 µm.(188) (C) Rivastigmine concentration in various 
organs after intravenous injection to rat models. Riv represents administration on free Rivastigmine. Riv-
NP represents Rivastigmine loaded poly(n-butylcyanoacrylate) nanoparticle. Riv-NP-PS 80 represents 
nanoparticles encapsulating Rivastigmine coating with 1% polysorbate 80.(189) (D) Tacrine 
concentration in various organs after intravenous injection to rat models. Tac represents the 
administration of free Tacrine. Tac-NP represents Tacrine loaded poly(n-butylcyanoacrylate) 
nanoparticle. Tac-NP-PS 80 represents nanoparticles encapsulating Tacrine coating with 1% polysorbate 
80.(190) (E) Resonance units of liposomes over time that represent their preferential binding to β-
amyloid monomers, oligomers, or fibrils. All liposomes are constituted of sphingomyelin from bovine 
brain (Sm) and cholesterol (Chol) (Sm:Chol 1:1). Upper figures have dimyristoylphosphatidic acid (PA) as 
the third component to combine with Sm and Chol. Lower figures have cardiolipin (CL) as the third 
component to combine with Sm and Chol. Left figures have 5 molar % and right figures have 20 molar % 
of the third component.(191)  
Figure 9. (A) The percent of dopamine in rat striatum in a 4-h time period. Single dosage (6–12 mg/kg) 
was injected. DA stands for dopamine. Vehicle = chitosan nano particles (CSNP). CSNP stands for 
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chitosan nanoparticles. *p < 0.05, **p < 0.01, ***p < 0.001 versus respective vehicle; #p < 0.05, ##p < 
0.01 versus respective DA/CSNPs (5) (6 mg/kg). Arrow shows the administration time.(202) (B) Confocal 
microscopy of cortical astrocytes treated with vehicle (H2O) (upper) and C3 fullerene (the tris malonic 
acid C60 adducts) (lower). Superoxide-sensitive dihydroethidium (DHE) was used as the fluorescent 
compound and decreasing fluorescent in the sample containing C3 showed that C3 resulted in lower 
mitochondrial superoxide anion production.(208)  
Figure 10. (A) Glutamate (Glu) receptors blocking of fullerenol. Glu induced free intracellular calcium is 
believed to be the reason for neurotoxicity. Cultures A-E all were treated with 50 µM fullerenol. Sample 
A contained no Glu, B-E related to the 0.5, 1, 3, and 5 minutes after treatment with Glu, F contained no 
Glu and no fullerenol and G contained no fullerenol but, 0.25 mM of Glu. Comparison between G and E 
clearly showed the effect of fullerenol on free calcium decrease.(210) (B) The effect of short-interfering 
RNA (siRNA)-loaded modified cyclodextrin (CD) on the mutant Huntington (HTT) gene expression in a rat 
striatal cell line. Knockdown of HTT gene expression was obtained with PCR.(214) 
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